Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

80%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

N/ANon-phased studies

4(80.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(1)

Detailed Status

Completed4

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (20.0%)

N/A4 (80.0%)

Trials by Status

unknown120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

completednot_applicable

Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT

NCT02456246

completednot_applicable

FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer

NCT02995889

completednot_applicable

FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer

NCT02995902

completedphase_1

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

NCT01143779

unknownnot_applicable

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

NCT01308905

Clinical Trials (5)

Showing 5 of 5 trials

NCT02456246Not Applicable

Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT

Completed

NCT02995889Not Applicable

FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer

Completed

NCT02995902Not Applicable

FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer

Completed

NCT01143779Phase 1

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

Completed

NCT01308905Not Applicable

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5